Kymera Therapeutics said in its third quarter update that it has completed the 16 week placebo controlled portion of BROADEN2, the Phase 2b study of KT-621 in moderate to severe atopic dermatitis, and expects to report results before the end of 2026 after study closeout. KT-621 is a once daily oral degrader of STAT6, the transcription factor that carries interleukin 4 and interleukin 13 signalling, the same pathway blocked by Sanofis and Regenerons Dupixent. Some 98 percent of eligible patients entered the 52 week open label extension.
Management has set the benchmark itself. Chief executive Nello Mainolfi reiterated that the company expects week 16 efficacy in the ballpark of dupilumab, while cautioning that cross trial comparisons have limits. STAT reported on November 2 that Jefferies analysts have called the results one of the most impactful immunology and inflammation readouts of the year, and that Visible Alpha consensus forecasts nearly 4 billion dollars of KT-621 sales by 2035, including more than 3 billion dollars in eczema. Those are analyst expectations ahead of data, not results.
The only human efficacy data so far come from the earlier Phase 1b BroADen study, a single arm, open label trial in 22 patients treated for 28 days. In that study, median STAT6 reduction was 94 percent in skin and 98 percent in blood, mean Eczema Area and Severity Index scores fell 63 percent, and 29 percent of patients reached EASI-75. There was no placebo arm, so those figures cannot separate drug effect from natural variation and trial effects, which is exactly what BROADEN2 is designed to do. Kymera said it worked to limit placebo response in BROADEN2 through site selection and screening procedures, and it released no efficacy data ahead of the readout.
The rest of the update frames the stakes. Kymera plans a first Phase 3 eczema study by mid 2027 if the data support it and the FDA agrees, is enrolling a Phase 2b asthma study with results expected in late 2027, and reported Phase 1 data for KT-579, an oral IRF5 degrader, with more than 90 percent degradation at top doses and a lupus trial planned for early 2027. The company ended September with about 1.6 billion dollars in cash and investments, which it says funds operations into 2029. Third quarter earnings per share were a loss of 1.32 dollars against a 1.26 dollar consensus loss, per reporting of the print on October 30.